5:53 PM · 27 November 2020

Moderna stock rose 17% on AstraZeneca’s vaccine news

Moderna (MRNA.US) — stock surged over 17% in response to the news that AstraZeneca’s (AZN.US) CEO said the company would run another trial on its coronavirus vaccine candidate amid questions over the drug’s effectiveness. Meanwhile Moderna's vaccine has already posted outstanding results in its late-stage trial. The company, in turn, is expected to seek an Emergency Use Authorization from the Food and Drug Administration within the next few days. Other drugmaker’s Pizer (PFE.US) and BioNTech (BNTX.US), which are also working on their own vaccine, gained 1.7% and 4.4%, respectively.

Moderna (MRNA.US) stock launched today’ s session with a bullish price gap and painted fresh all-time high at $130.00. However bulls failed to uphold momentum and price pulled back to the $119.27 level. Source: xStation5

28 September 2026, 7:27 PM

Daily Summary: Lack of progress in negotiations weighs on Wall Street and precious metals (28.09.2026)

28 September 2026, 5:24 PM

US Open: Wall Street starts the week in red (28.09.2026)

25 September 2026, 6:54 PM

Daily summary: Nasdaq gains despite rising bond yields 📈 Oil below $100

25 September 2026, 5:56 PM

Defense stocks after the correction 🚩 Opportunity or trap?

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits